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Preeclampsia and related hypertensive disorders of pregnancy affect 
approximately 5% of all births. Worldwide, 10 million women develop 
preeclampsia, with about 80,000 women dying from preeclampsia and related 
complications each year. Although the precise aetiology of preeclampsia has been 
a source of long-standing debate, overwhelming opinion attributes the 
development of preeclampsia to impaired placentation in early pregnancy. 
However, more recent evidence has demonstrated that placental histology is 
invariably normal in preeclampsia and that the majority of neonates born of 
preeclamptic mothers are either normal or larger in size than expected.1,2 These 
findings undermine the fundamental assertion that abnormal placental 
development is a primary aetiological factor for preeclampsia and have led 
researchers to seek alternative hypotheses. One emerging and biologically 
plausible theory is that preeclampsia occurs as a consequence of cardiovascular 
maladaptation to pregnancy (TED talk at: https://bit.ly/2JP0oNT).  The findings 
that cardiovascular dysfunction precedes preeclampsia, cardiovascular signs 
predominate in the clinical syndrome and that the risk of cardiovascular disease 
persists for several decades postpartum is compelling evidence for the 
cardiovascular origins of preeclampsia.3-6 The concept that placental dysfunction 
is secondary to a maternal disorder is not new when one considers the clinical 
similarities between preeclampsia and gestational diabetes – both pregnancy-
specific conditions that are ‘cured’ by birth.7 
 
The cardiovascular origin of preeclampsia hypothesis continues to be of 
relevance when interpreting the conduct and outcome of the recently-published 
ASPRE trial in the New England Journal of Medicine.8 Researchers conducted a 
double-blind, placebo-controlled trial in 13 European centres, where 1776 
women with singleton pregnancies identified to be at high-risk for preterm 
(birth before 37 weeks) preeclampsia, were randomised to receive either aspirin 
150mg per day or placebo from 11 to 36 weeks of gestation. The study 
demonstrated that preterm preeclampsia occurred in 1.6% in the aspirin group, 
as compared with 4.3% in the placebo group – a 60% reduction in preterm 
preeclampsia (OR: 0.38; 95% CI: 0.20 to 0.74). Adherence to therapy was 
formally evaluated as good in 80% of the participants, with no demonstrable 
difference in the incidence of neonatal or maternal adverse outcomes in either 
arm of the study. 
 
The ASPRE study has several implications for clinical practice, beginning with 
demonstrating effective early pregnancy screening for preterm preeclampsia. In 
the UK, identification of women as high-risk for preeclampsia is currently based 
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on a checklist of maternal characteristics and medical history as defined by 
National Institute for Health and Care Excellence (NICE) guidelines. The ASPRE 
study used an algorithm that combined known risk factors with mean arterial 
pressure (MAP), uterine artery pulsatility index and serum placental growth 
factor (PlGF) taken at 11 to 13 weeks’ gestation. The use of this algorithm more 
than doubled the sensitivity for preterm preeclampsia from 40% for the NICE 
recommended policy to 82%, thereby making a compelling case for the routine 
implementation of this screening protocol.9 It should be noted that the screening 
test utilises cardiovascular indices (MAP, uterine artery pulsatility index and 
PlGF) and preeclampsia prophylaxis is achieved using a drug with established 
vascular effects. Furthermore, the study settles recent uncertainty surrounding 
the appropriate dosage and timing of aspirin prophylaxis.10 These findings are all 
further support for the cardiovascular origin of preeclampsia. 
 
It has long been presumed by researchers interested in preeclampsia that 
defects of trophoblast (placental) development, motility, invasion and function 
are intrinsic defects that then influence uterine perfusion by way of inadequate 
spiral (uterine) artery invasion and remodelling. A re-examination of this 
assumption reveals that either it is incorrect or that - uniquely in human biology 
- placental end organ tissue structure influences upstream vascular perfusion. 
Recent research supports the more likely scenario that primary impaired uterine 
perfusion may lead to inadequate trophoblast invasion and function.11 
It is also remarkable that for a disease, which has been clinically recognised for 
over a century and with a significant human toll, no diagnostic test exists. The 
validation of an effective multimodal ASPRE screening test in early pregnancy for 
preeclampsia also raises the possibility and hope that combining cardiovascular 
markers may provide a clinically valuable predictive or diagnostic test in later 
pregnancy.12 
 
Arguably, the largest burden of disease lies in the maternal postpartum legacy of 
preeclampsia. More recent epidemiological data demonstrates that the peak 
onset of chronic hypertension following preeclampsia occurs in the first two-
three years following pregnancy – not decades later as previously presumed.3  
Indeed, preterm preeclampsia is a stronger risk factor than smoking for the 
development of stroke and other cardiovascular diseases in women. This finding 
is consistent with the data showing echocardiographic evidence of occult 
diastolic dysfunction in the majority normotensive women one year following a 
pregnancy complicated by preterm preeclampsia.13 Although the APSRE study 
demonstrated an undeniable and desirable benefit in pregnancy outcome, it 
remains to be determined whether aspirin therapy in women at high-risk of 
preterm preeclampsia will ameliorate the deleterious long-term maternal 
cardiovascular consequences of pregnancy. 
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